Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance
January 25, 2022 – San Diego, CA – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations. Mr. O’Neill brings extensive experience leading Quality, Manufacturing, and Operational Excellence Teams in the pharmaceutical and bio-pharmaceutical industry.
Mr. O’Neill joins Aji Bio-Pharma after 25 years at Allergan, where he held a number of Quality and Operational leadership positions in biologics manufacturing and development with responsibility both in Ireland and US operations. His most recent roles include Executive Director Quality Operations and Executive Director Risk Management and Compliance, where he was responsible for leading a team in developing standard policies and processes for data management and controls across a network of 14 sites.
“We are excited to welcome Tony O’Neill to our leadership team at Aji Bio-Pharma,” said Nobu Shimba, President and CEO of Aji Bio-Pharma, US. “With his extensive management experience, we are confident that Tony will be a strong leader for our teams as we provide our clients’ unique drug programs with dedicated attention, strong regulatory support, and focused quality. As we continue to expand our capacity and service offerings, including the addition of our new multi-purpose fill/finish suite, Tony’s expertise will be integral in ensuring the required sterility and regulatory standards are met for both cGMP clinical and commercial manufacturing.”
Über Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services ist ein vollintegriertes Auftragsentwicklungs- und Produktionsunternehmen mit Standorten in Belgien, den Vereinigten Staaten, Japan und Indien, das umfassende Dienstleistungen in den Bereichen Entwicklung, cGMP-konforme Herstellung sowie aseptische Abfüllung und Verpackung für klein- und großmolekulare Wirkstoffe und Zwischenprodukte anbietet. Ajinomoto Bio-Pharma Services bietet eine breite Palette innovativer Plattformen und Kompetenzen für präklinische und Pilotprogramme bis hin zu kommerziellen Mengen, darunter die Corynex®-Proteinexpressionstechnologie, Oligonukleotidsynthese, Antikörper-Wirkstoff-Konjugate (ADC), hochwirksame Wirkstoffe (HPAPI), Biokatalyse, kontinuierliche Durchflussfertigung und vieles mehr. Ajinomoto Bio-Pharma Services hat es sich zur Aufgabe gemacht, ein hohes Maß an Qualität und Service zu bieten, um den Bedürfnissen seiner Kunden gerecht zu werden. Erfahren Sie mehr: www.AjiBio-Pharma.com
